Ocuphire Pharma Inc
NASDAQ:OCUP
Balance Sheet
Balance Sheet Decomposition
Ocuphire Pharma Inc
Ocuphire Pharma Inc
Balance Sheet
Ocuphire Pharma Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
10
|
10
|
12
|
9
|
9
|
9
|
16
|
25
|
43
|
51
|
|
| Cash Equivalents |
10
|
10
|
12
|
9
|
9
|
9
|
16
|
25
|
43
|
51
|
|
| Short-Term Investments |
23
|
13
|
9
|
18
|
6
|
3
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
2
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
33
|
25
|
21
|
28
|
16
|
13
|
18
|
26
|
49
|
54
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
34
N/A
|
25
-26%
|
21
-15%
|
28
+34%
|
16
-43%
|
13
-19%
|
18
+36%
|
26
+48%
|
49
+88%
|
54
+10%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
0
|
1
|
1
|
0
|
1
|
2
|
1
|
2
|
|
| Accrued Liabilities |
2
|
2
|
1
|
2
|
3
|
1
|
2
|
2
|
1
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
3
|
2
|
3
|
3
|
3
|
3
|
4
|
3
|
4
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
4
|
3
|
2
|
8
|
2
|
0
|
28
|
0
|
0
|
0
|
|
| Total Liabilities |
7
N/A
|
6
-13%
|
4
-34%
|
12
+189%
|
5
-52%
|
3
-45%
|
31
+935%
|
4
-88%
|
3
-29%
|
4
+47%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
91
|
106
|
115
|
140
|
155
|
163
|
33
|
89
|
71
|
81
|
|
| Additional Paid In Capital |
118
|
124
|
132
|
157
|
165
|
173
|
19
|
112
|
118
|
131
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
27
N/A
|
19
-29%
|
17
-9%
|
17
-2%
|
11
-37%
|
10
-6%
|
13
N/A
|
22
N/A
|
46
+108%
|
50
+8%
|
|
| Total Liabilities & Equity |
34
N/A
|
25
-26%
|
21
-15%
|
28
+34%
|
16
-43%
|
13
-19%
|
18
+36%
|
26
+48%
|
49
+88%
|
54
+10%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
1
|
1
|
1
|
11
|
19
|
21
|
24
|
|